Back to Search
Start Over
Validation of a commercial line blot for the detection of serum anti-Ro60 autoantibodies.
- Source :
-
Pathology [Pathology] 2022 Dec; Vol. 54 (7), pp. 900-903. Date of Electronic Publication: 2022 Jul 16. - Publication Year :
- 2022
-
Abstract
- Serum anti-Ro60 is one the most frequently encountered autoantibodies in the diagnostic immunopathology laboratory and in clinical practice. A large variety of assays are available to detect this including the popular multiplex line immunoblot (IB) assay. We evaluated the analytical performance of the IB for anti-Ro60 detection, using the counterimmunoelectrophoresis (CIEP) method as the 'gold standard'. We also undertook a survey of international laboratories, who use the IB, about their reporting practices for anti-Ro60. Using the manufacturer's reported cut-off of 15 units, the IB has an analytical sensitivity of 90.9% and specificity of 99.3% for anti-Ro60 detection. The optimal cut-off to balance sensitivity and specificity was determined to be 5 units with a sensitivity of 100% and specificity of 97.4%. Most laboratories use the manufacturer's specified cut-off (15 units) when determining a positive anti-Ro60 result. Whilst the commercial IB generally performs well, laboratorians need to be mindful of the limitations of IB in detecting antibodies that recognise conformational epitopes and what cut-offs they use. A vast majority of laboratories could potentially miss detection of this clinically important autoantibody.<br /> (Crown Copyright © 2022. Published by Elsevier B.V. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 1465-3931
- Volume :
- 54
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Pathology
- Publication Type :
- Academic Journal
- Accession number :
- 35931495
- Full Text :
- https://doi.org/10.1016/j.pathol.2022.05.009